Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE trial
2024-518036-36-03Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of talazoparib in breast cancer, sponsored by Erasmus MC. Primary endpoint: Progression-free survival at 4 months (PFS4). Started Jan 2025; status: completed.
02
Drugs
talazoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-518036-36-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518036-36-03.